31results about How to "Inhibition of degranulation" patented technology

The invention relates to the biotechnology field, and more specifically, the invention discloses a human monoclonal antibody against IgE, a preparation method and a purpose thereof. According to the invention, a natural human phage antibody library of large capacity is constructed;; a human antibody 2E19 strain against IgE is obtained through screening from the library; an amino acid sequence of a heavy chain variable region is expressed as SEQ ID NO: 6; and the amino acid sequence of a light chain variable region is expressed as SEQ ID NO: 8. Besides, the invention also discloses the preparation method of the antibody 2E19, as well as a nucleotide sequence for encoding the antibody 2E19 and an expression vector and a host cell comprising the nucleotide sequence. The antibody 2E19 of the invention has a higher antibody affinity, so as to be able to obviously inhibit degranulation caused by the combination of IgE and FC epsilon RI on a cell surface, and the antibody 2E19 does not combine with the IgE combined with the FC epsilon RI on the cell surface. The antibody 2E19 of the invention could be used for the preparation of a medicine for treating hypersensitivity diseases, especially for treating allergic asthma.

The invention discloses a medicinal composition for treating child asthmatic suffocating pneumonia. The medicinal composition is characterized by being processed from multiple Chinese medicines in parts by weight: 1-3 parts of Chinese honey locust, 6-9 parts of loguat leaf, 10-15 parts of european hop flower, 10-15 parts of waxgourd seed, 6-9 parts of common bluebeard herb, 6-9 parts of platycodon root, 10-15 parts of red clover flower and inflorescence, 6-9 parts of whiteflower hogfennel root and 1-3 parts of borneol. As proved by clinical experiments, the medicinal composition for treating child asthmatic suffocating pneumonia has the characteristics of good curative effect and high safety, and is worthy of clinical application and popularization.

The invention discloses the application of a compound in the preparation of antiallergic medicine, characterized in that the molecular formula of the compound is C 29 H 27 NO 8 , its chemical structural formula is: the present invention finds that the compound T-5224 can significantly inhibit the release of β-aminoglycosidase in mast cells, has the effect of significantly inhibiting the degranulation of mast cells, and can significantly inhibit allergy in mice reaction. This fully shows that the T-5224 compound can be used to prepare antiallergic drugs and has broad application prospects.